)
Edge6 Mar 2026
Upvoted: The Story of Reddit
How Reddit built a unique platform around communities and conversation, turning human insight and intent into a distinctive business model.
MedCap
MedCap (MCAP) investor relations material
MedCap Q4 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q4 2025 earnings summary6 Feb, 2026
Executive summary
Achieved 25% sales growth in Q4 2025 and 17% full-year growth, with 10% organic growth and strong performance across all segments.
Adjusted EBITA grew by 68% in Q4 and 26% for the year, with a Q4 margin of 19.1% excluding acquisition-related one-time effects.
Three acquisitions completed: Danrehab, XGX Pharma, and LivAssured (Nightwatch), expanding the portfolio and geographic reach.
Continued ambition for further acquisitions leveraging a strong balance sheet.
All business areas contributed to growth, with particularly strong performance in Assistive Tech and MedTech.
Financial highlights
Q4 2025 net sales reached 591.0 MSEK, up 25% year-over-year; full-year net sales were 2,108.0 MSEK, up 17%.
Adjusted EBITA for Q4 was 112.9 MSEK, up 68% year-over-year; full-year adjusted EBITA was 385.6 MSEK, up 26%.
EBITA margin for Q4 was 19.1%; full-year margin was 18.4%.
Profit after tax for the year was 220.7 MSEK; earnings per share 14.7 SEK (adjusted 14.5 SEK).
Cash flow from operating activities for the year was 342.7 MSEK.
Outlook and guidance
Margin in Specialty Pharma expected to improve in the second half of 2026 and beyond.
Ongoing focus on acquisitions and increasing use of the strong balance sheet.
Specialty Pharma margin improvement timeline
Future M&A capacity given rising net debt
Key drivers of MedTech/Assistive Tech organic growth
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from MedCap
- Strong growth in life science through buy & build, with 19% sales and 29% EBITA CAGR.MCAP
Company presentation16 Jan 2026 - Strong revenue growth and strategic acquisitions drive expansion in life science markets.MCAPAGM 2025 presentation16 Jan 2026
- Achieved SEK 1,807 million revenue in 2024 with a 23% EBITA CAGR, driven by acquisitions.MCAPCompany presentation16 Jan 2026
- Life science group achieves robust growth via acquisitions and innovation in core business areas.MCAPSEB Nordic Seminar presentation16 Jan 2026
- Sales up 14% in 2024, but Specialty Pharma weakness weighed on EBITA.MCAPQ4 202428 Oct 2025
- Q3 saw double-digit sales and profit growth, led by Assistive Tech and MedTech, despite Specialty Pharma headwinds.MCAPQ3 202428 Oct 2025
- Q2 net sales up 19% and EBITA up 25%, led by strong Assistive Tech and MedTech growth.MCAPQ2 202428 Oct 2025
- 7% sales growth and 17% EBITA margin driven by Assistive Tech, despite Specialty Pharma weakness.MCAPQ1 202528 Oct 2025
- Q2 saw 14% sales and 20% EBITA growth, with acquisitions fueling expansion.MCAPQ2 202528 Oct 2025
Next MedCap earnings date
Q1 202629 Apr, 2026
MedCap
Next MedCap earnings date
Q1 202629 Apr, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage